What does ctmx stand for?
CTMX | Complete CytomX Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. CTMX | Complete CytomX Therapeutics Inc. stock news by MarketWatch.
What's the upside for CytomX Therapeutics (ctmx) stock?
Their CTMX stock forecasts range from $1.50 to $11.00. On average, they predict CytomX Therapeutics' share price to reach $4.89 in the next year. This suggests a possible upside of 241.9% from the stock's current price.
What are analysts' target prices for CytomX Therapeutics' stock?
10 equities research analysts have issued 1 year target prices for CytomX Therapeutics' shares. Their predictions range from $13.24 to $34.00. On average, they anticipate CytomX Therapeutics' stock price to reach $20.91 in the next twelve months.
What are Wall Street's 12-month price targets for CytomX Therapeutics (ctmx)?
11 Wall Street analysts have issued 12-month price targets for CytomX Therapeutics' shares. Their CTMX stock forecasts range from $1.50 to $11.00. On average, they predict CytomX Therapeutics' share price to reach $4.89 in the next year.
See more
Is CTMX a good stock to buy?
Out of 11 analysts, 3 (27.27%) are recommending CTMX as a Strong Buy, 2 (18.18%) are recommending CTMX as a Buy, 6 (54.55%) are recommending CTMX as a Hold, 0 (0%) are recommending CTMX as a Sell, and 0 (0%) are recommending CTMX as a Strong Sell.
Why is CytomX stock dropping?
The steep decline came after the company announced disappointing preliminary results from a phase 2 study evaluating CX-2029 in treating patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcinoma (HNSCC).
Is CytomX a buy?
The consensus rating for CytomX Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how CTMX compares to other companies.
Is CytomX a public company?
CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock.
Is CTMX stock a buy right now?
6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currentl...
Will CytomX Therapeutics' stock price go up in 2022?
6 brokerages have issued 1-year target prices for CytomX Therapeutics' shares. Their forecasts range from $6.00 to $16.00. On average, they expect...
How has CytomX Therapeutics' stock price performed in 2022?
CytomX Therapeutics' stock was trading at $4.33 at the beginning of the year. Since then, CTMX stock has decreased by 54.5% and is now trading at $...
When is CytomX Therapeutics' next earnings date?
CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were CytomX Therapeutics' earnings last quarter?
CytomX Therapeutics, Inc. (NASDAQ:CTMX) issued its quarterly earnings results on Thursday, May, 5th. The biotechnology company reported ($0.37) EPS...
Who are CytomX Therapeutics' key executives?
CytomX Therapeutics' management team includes the following people: Dr. Sean A. McCarthy D.Phil. , DPHIL, Chairman & CEO (Age 55, Pay $980.33k)...
What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?
11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Glassdoor.com . Sean A McCarthy has an approval rating of 65% among CytomX Ther...
Who are some of CytomX Therapeutics' key competitors?
Some companies that are related to CytomX Therapeutics include Nkarta (NKTX) , Amryt Pharma (AMYT) , ANI Pharmaceuticals (ANIP) , IDEAYA Biosci...
What other stocks do shareholders of CytomX Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences...
Where is CytomX based?
What is the P/E ratio of Cytomx Therapeutics?
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
What is MarketBeat community ratings?
The P/E ratio of CytomX Therapeutics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is Cytomx Therapeutics a buy?
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote “Outperform” if you believe CTMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Does CytomX pay dividends?
CytomX Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.
What is CytomX Therapeutics?
CytomX Therapeutics does not currently pay a dividend.
What is market cap?
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform.
What time do you trade in the pre market?
Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.
Does market cap include convertible securities?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
How does MarketBeat calculate stock ratings?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Does MarketBeat like Cytomx?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.